D. E. Shaw & Co. Inc. Purchases 141,307 Shares of LifeMD, Inc. (NASDAQ:LFMD)

D. E. Shaw & Co. Inc. lifted its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 825.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 158,423 shares of the company's stock after buying an additional 141,307 shares during the period. D. E. Shaw & Co. Inc. owned about 0.37% of LifeMD worth $784,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Prudential Financial Inc. increased its holdings in shares of LifeMD by 19.3% during the 4th quarter. Prudential Financial Inc. now owns 13,605 shares of the company's stock worth $67,000 after acquiring an additional 2,200 shares during the last quarter. Rhumbline Advisers increased its stake in LifeMD by 6.1% in the fourth quarter. Rhumbline Advisers now owns 48,689 shares of the company's stock valued at $241,000 after acquiring an additional 2,814 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of LifeMD by 26.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock worth $70,000 after buying an additional 2,895 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of LifeMD by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 822,217 shares of the company's stock worth $4,071,000 after buying an additional 2,984 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in LifeMD by 44.7% in the fourth quarter. Wells Fargo & Company MN now owns 18,732 shares of the company's stock valued at $93,000 after buying an additional 5,791 shares in the last quarter. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Price Performance

NASDAQ LFMD traded up $0.02 on Thursday, reaching $11.49. The company had a trading volume of 1,218,222 shares, compared to its average volume of 985,057. The firm has a market cap of $522.20 million, a price-to-earnings ratio of -17.95 and a beta of 2.22. LifeMD, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $12.19. The business has a 50 day moving average of $7.30 and a two-hundred day moving average of $6.24.

LifeMD (NASDAQ:LFMD - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.05. The firm had revenue of $65.70 million for the quarter, compared to the consensus estimate of $62.47 million. As a group, research analysts predict that LifeMD, Inc. will post -0.56 earnings per share for the current fiscal year.

Insider Transactions at LifeMD

In related news, CMO Jessica Friedeman sold 30,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $5.66, for a total transaction of $169,800.00. Following the transaction, the chief marketing officer now directly owns 170,000 shares of the company's stock, valued at approximately $962,200. This represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Justin Schreiber sold 21,995 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $7.53, for a total value of $165,622.35. Following the completion of the sale, the chief executive officer now directly owns 2,553,726 shares of the company's stock, valued at $19,229,556.78. This trade represents a 0.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,995 shares of company stock valued at $724,422 in the last quarter. 15.97% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of LifeMD in a report on Wednesday, April 30th. B. Riley raised LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $15.00 price target on shares of LifeMD in a research note on Tuesday, March 11th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, LifeMD has an average rating of "Buy" and a consensus price target of $11.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.